We analyzed the potential of abiraterone acetate ( henceforth abiraterone ) to reduce androgen levels below lower limits of quantification ( LLOQ ) and explored the association with changes in PSA decline in metastatic castration-resistant prostate cancer ( mCRPC ) patients .